Usefulness and limitations of QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients: Proposal to decrease the lower cutoff level for assessing latent tuberculosis infection

Modern Rheumatology

Volumn 20, Issue 1, 2010, Pages 18-23

  Maeda, Tomoyo ^a   Banno, Shogo ^a,b   Maeda, Shinji ^a   Naniwa, Taio ^a   Hayami, Yoshihito ^a   Watanabe, Maiko ^a   Itoh, Rei ^a   Sato, Shigeki ^a   Ueda, Ryuzo ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NAGOYA CITY UNIVERSITY HOSPITAL   (Japan)

Author keywords

Interferon release assay; Latent tuberculosis infection; Rheumatoid arthritis; Tuberculin skin test; Tuberculosis

Indexed keywords

BACTERIUM ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; GLYCOLIPID; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST;

ADULT; ANTIGENS, BACTERIAL; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; ROC CURVE; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY;

EID: 76649112393     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0226-5     Document Type: Article

References (23)

1. L Carmona C Hernandez-Garcia C Vadillo E Pato A Balsa I Gonzalez-Alvaro, et al. 2003 Increased risk of tuberculosis in patients with rheumatoid arthritis J Rheumatol 300 1436 1439 (Pubitemid 36835436)
2. SS Seong CB Choi JH Woo KW Bae CL Joung WS Uhm, et al. 2007 Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers J Rheumatol 34 706 711 1:CAS:528:DC%2BD2sXlsVWju78%3D 17309133
3. J Askling CM Fored L Brandt E Baecklund L Bertilsson L Coster, et al. 2005 Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden Arthritis Rheum 52 1986 1992 10.1002/art.21137 1:CAS:528:DC%2BD2MXnsl2gsLY%3D 15986370 (Pubitemid 40994319)
4. KL Winthrop JN Siegel J Jereb Z Taylor MF Iademarco, et al. 2005 Tuberculosis associated with therapy against tumor necrosis factor α Arthritis Rheum 52 2968 2974 10.1002/art.21382 1:CAS:528:DC%2BD2MXhtF2msr3I 16200576 (Pubitemid 41447075)
5. J Keane S Gershon RP Wise E Mirabile-Levens J Kasznica WD Schwieterman, et al. 2001 Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 345 1098 1104 10.1056/NEJMoa011110 1:CAS:528:DC%2BD3MXnsFShsr0%3D 11596589 (Pubitemid 34940777)
6. MA Gardam EC Keystone R Menzies S Manners E Skamene R Long, et al. 2003 Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management Lancet Infect Dis 3 148 155 10.1016/S1473-3099(03)00545- 0 1:CAS:528:DC%2BD3sXislKmsLo%3D 12614731 (Pubitemid 36278124)
7. L Carmona JJ Gómez-Reino V Rodríguez-Valverde D Montero E Pascual-Gómez EM Mola, et al. 2005 Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists Arthritis Rheum 52 1766 1772 10.1002/art.21043 1:CAS:528:DC%2BD2MXlvFChur0%3D 15934089 (Pubitemid 40852885)
8. T Takeuchi Y Tatsuki Y Nogami N Ishiguro Y Tanaka H Yamanaka, et al. 2008 Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis Ann Rheum Dis 67 189 194 10.1136/ard.2007.072967 1:CAS:528:DC%2BD1cXisFCqtrg%3D 17644554 (Pubitemid 351183307)
9. R Koike T Takeuchi K Eguchi N Miyasaka Japan College of Rheumatology 2007 Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis Mod Rheumatol 17 451 458 10.1007/s10165-007-0626-3 1:CAS:528:DC%2BD1cXisFCjtbo%3D 18084695
10. T Koike M Harigai S Inokuma K Inoue N Ishiguro J Ryu, et al. 2009 Postmarketing surveillance of the safety and effectiveness of etanercept in Japan J Rheumatol 36 898 906 10.3899/jrheum.080791 1:CAS:528: DC%2BD1MXmtV2iurw%3D 19332630
11. D Menzies R Long A Trajman MJ Dion J Yang H Al Jahdali, et al. 2008 Adverse events with4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial Ann Intern Med 149 689 697 19017587
12. M Pai A Zwerling D Menzies 2008 Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update Ann Intern Med 149 177 184 18593687
13. Y Kobashi K Mouri S Yagi Y Obase N Miyashita N Okimoto, et al. 2008 Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis Chest 133 1196 1202 10.1378/chest.07-1995 18263689 (Pubitemid 351685526)
14. T Mori M Sakatani F Yamagishi T Takashima Y Kawabe K Nagao, et al. 2004 Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens Am J Respir Crit Care Med 170 59 64 10.1164/rccm.200402-179OC 15059788
15. R Maekura Y Okuda M Nakagawa T Hiraga S Yokota M Ito, et al. 2001 Clinical evaluation of anti-tuberculous glycolipid immunoglobulin G antibody assay for rapid serodiagnosis of pulmonary tuberculosis J Clin Microbiol 39 3603 3608 10.1128/JCM.39.10.3603-3608.2001 1:CAS:528:DC%2BD3MXnslKiu74%3D 11574580 (Pubitemid 32954509)
16. M Kawamura N Sueshige K Imayoshi I Yano R Maekura H Kohno 1997 Enzyme immunoassay to detect antituberculous glycolipid antigen (anti-TBGL antigen) antibodies in serum for diagnosis of tuberculosis J Clin Lab Anal 11 140 145 10.1002/(SICI)1098-2825(1997)11:3<140::AID-JCLA4>3.0.CO;2-E 1:CAS:528:DyaK2sXjtlKqsb8%3D 9138102 (Pubitemid 27194558)
17. D Ponce de Leon E Acevedo-Vasquez A Sanchez-Torres M Cucho J Alfaro R Perich, et al. 2005 Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in population with a high prevalence of tuberculosis Ann Rheum Dis 64 1360 1361 10.1136/ard.2004.029041 1:CAS:528:DC%2BD2MXhtVChu7zE 16100342 (Pubitemid 41206259)
18. P Efthimiou S Sood 2007 QuantiFERON TB Gold Test: the new standard for screening of latent tuberculosis in patients with rheumatoid arthritis? Ann Rheum Dis 66 276 10.1136/ard.2006.061184 17127686 (Pubitemid 46226073)
19. D Ponce de Leon E Acevedo-Vasquez S Alvizuri C Gutierrez M Cucho J Alfaro, et al. 2008 Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population J Rheumatol 3 776 781
20. A Pratt K Nicholl L Kay 2007 Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience Rheumatology (Oxford) 46 1035 1036 10.1093/rheumatology/kem064 1:CAS:528:DC%2BD2sXot1Sgtrg%3D (Pubitemid 47062518)
21. Wu-Hsieh BA, Chen CK, Chang JH, Lai SY, Wu CH, Cheng WC, et al. Long-lived immune response to early secretory antigenic target 6 in individuals who had recovered from tuberculosis. Clin Infect Dis 2001;33:1336-40.
22. Y Kobashi T Sugiu Y Ohue K Mouri Y Obase N Miyashita, et al. 2008 Long-term follow-up of the QuantiFERON TB-2G test for active tuberculosis disease Intern Med 47 1957 1961 10.2169/internalmedicine.47.1313 19015607
23. P Emery GS Panayi AM Nouri 1984 Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis Clin Exp Immunol 57 123 129 1:STN:280:DyaL2c3mtVSmsQ%3D%3D 6611230